Provided by Tiger Trade Technology Pte. Ltd.

Adicet Bio, Inc.

7.14
+0.31004.54%
Pre-market: 7.320.1800+2.52%06:01 EDT
Volume:211.06K
Turnover:1.49M
Market Cap:66.75M
PE:-0.68
High:7.28
Open:6.80
Low:6.71
Close:6.83
52wk High:17.44
52wk Low:6.01
Shares:9.35M
Float Shares:8.42M
Volume Ratio:0.26
T/O Rate:2.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-10.5201
EPS(LYR):-16.9493
ROE:-78.08%
ROA:-41.66%
PB:0.56
PE(LYR):-0.42

Loading ...

Adicet Bio Grants New-Hire Stock Options for 725 Shares at $7.14 Each Under Inducement Plan

Reuters
·
11 hours ago

Adicet Bio Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
11 hours ago

Adicet Bio price target raised to $28 from $25 at Wedbush

TIPRANKS
·
Sep 29

Adicet Bio Price Target Raised to $28.00/Share from $25.00 by Wedbush

Dow Jones
·
Sep 29

Wedbush Adjults Adicet Bio Price Target to $28 From $25, Maintains Outperform Rating

MT Newswires Live
·
Sep 28

Adicet Bio, Inc. : H.c. Wainwright Raises Target Price to $34 from $27

THOMSON REUTERS
·
Sep 28

Adicet Bio trading halted, volatility trading pause

TIPRANKS
·
Sep 28

NASDAQ Trade Halt Volatility Trading Pause at 09:30 Am

Reuters
·
Sep 28

Adicet Bio reports data from Phase 1 study of prula-cel

TIPRANKS
·
Sep 28

Adicet Bio Announces Positive Safety and Efficacy Data from Prula-Cel (Formerly Adi-001) Study in Patients with Systemic Lupus Erythematosus with or Without Lupus Nephritis

Reuters
·
Sep 28

Adicet Bio Says Prula-Cel Phase 1 Lupus Study Shows 54% DORIS Remission at 12 Months

Reuters
·
Sep 28

Adicet Bio, - All Patients Discontinued Immunosuppressants

THOMSON REUTERS
·
Sep 28

Adicet Bio, - Prula-Cel Shown to be Well Tolerated with no Crs Above Grade 2 and no Iec-Hs or Icans

THOMSON REUTERS
·
Sep 28

Adicet Bio, - at 12 Months, 54% Achieved Doris Remission and 50% Achieved Complete Renal Response

THOMSON REUTERS
·
Sep 28

Adicet Bio, - Anticipated Clinical Data Update in Lupus Nephritis/Systemic Lupus Erythematosus in Mid 2027

THOMSON REUTERS
·
Sep 28

Adicet Bio, - Plans to Initiate Pivotal Lupus Nephritis Trial Start-up Activities in Q4 2026

THOMSON REUTERS
·
Sep 28

U.S. Research Roundup-Chevron, Mobility Global, Tesla

Reuters
·
Sep 28

Adicet Bio to Present Phase 1 Prula-Cel Data in Systemic Lupus Erythematosus on Sept. 28, 2026 Webcast

Reuters
·
Sep 26

Adicet Bio Price Target Maintained with a $27.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 19

Adicet data update presents attractive opportunity, says H.C. Wainwright

TIPRANKS
·
Sep 19